Investing.com — Moderna , Inc. (NASDAQ:) shares surged 14% following remarks by Oracle (NYSE:) Chairman Larry Ellison on the transformative potential of artificial intelligence (AI) in healthcare, particularly in early cancer detection and the development of personalized vaccines.
Ellison’s comments underscored the potential for AI to revolutionize healthcare by identifying cancer early through blood tests and enabling the rapid creation of individualized vaccines. The boost in Moderna’s stock also comes on the heels of President Donald Trump’s announcement of a $500 billion private sector investment in AI infrastructure, which includes a joint venture known as Stargate with participation from OpenAI, SoftBank (TYO:), and Oracle. This initiative is set to bolster AI’s role in healthcare by establishing data centers and creating jobs.
The Oracle Chairman elaborated on how minuscule fragments of tumors circulating in the blood could be detected using AI-powered blood tests, leading to early cancer diagnosis. Subsequently, AI could play a crucial role in gene-sequencing cancerous tumors to formulate personalized vaccines. These mRNA vaccines could be produced robotically within 48 hours, offering a quick and personalized response to cancer treatment.
Although no specific analyst comments were provided, the market’s reaction to Ellison’s vision and the significant private sector investment in AI infrastructure reflects a strong investor interest in the intersection of healthcare and technology. Moderna’s leap in share price is indicative of the optimism surrounding the company’s potential role in this AI-driven healthcare future.
The implications of AI in healthcare, especially in the context of Moderna’s expertise in mRNA technology, appear to be resonating with investors. As the industry moves towards more personalized and efficient healthcare solutions, companies like Moderna stand at the forefront of these advancements, potentially reaping the benefits of increased investment and innovation in the field.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
